SEARCH

SEARCH BY CITATION

References

  • 1
    Lamers CBHM, Griffioen G, Van Hogezand RA, Veenendaal RA. Azathioprine: and update of clinical efficacy and safety information in inflammatory bowel disease. Scan J Gastroenterol 1999; 230(Suppl.): 1125.
  • 2
    Nielsen H, Vainer B, Rask-Madsen J. The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharm Ther 2001; 15: 1699708.
  • 3
    Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008; 28: 6238.
  • 4
    Le′mann M, Bouhnik Y, Kmieciak-Le Corguille M, et al. Treatment of Crohn's disease (CD) with 6-mercaptopurine (6-MP) in patients intolerant to azathioprine (AZA). Gastroenterology 1997; 112: A1025.
  • 5
    Bowen DG, Selby WS. Use of 6-mercpatopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45: 18103.
  • 6
    Hindorf U, Johansson A, Eriksson E, Kvifors E, Almer SHC. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 65461.